ID

15305

Beschreibung

Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent; ODM derived from: https://clinicaltrials.gov/show/NCT01511198

Link

https://clinicaltrials.gov/show/NCT01511198

Stichworte

  1. 25.05.16 25.05.16 -
Hochgeladen am

25. Mai 2016

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0

Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Diabetes NCT01511198

Eligibility Diabetes NCT01511198

  1. StudyEvent: Eligibility
    1. Eligibility Diabetes NCT01511198
Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
type 2 diabetic
Beschreibung

type 2 diabetic

Datentyp

boolean

Alias
UMLS CUI [1]
C0011860
treated with oha (oral hypoglycaemic agent monotherapy for at least 3 months. prior use of metformin is allowed
Beschreibung

oral hypoglycaemic agent

Datentyp

boolean

Alias
UMLS CUI [1]
C0359086
body mass index (bmi) between 27.0-42.0 kg/m^2 (inclusive)
Beschreibung

BMI

Datentyp

boolean

Alias
UMLS CUI [1]
C1305855
hba1c maximum 10% based on analysis from central laboratory
Beschreibung

hba1c

Datentyp

boolean

Alias
UMLS CUI [1]
C0019018
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
cardiac problems
Beschreibung

cardiac problems

Datentyp

boolean

Alias
UMLS CUI [1]
C0262402
uncontrolled treated/untreated hypertension
Beschreibung

untreated hypertension

Datentyp

boolean

Alias
UMLS CUI [1]
C0020538
proliferative retinopathy or known autonomic neuropathy
Beschreibung

proliferative retinopathy or known autonomic neuropathy

Datentyp

boolean

Alias
UMLS CUI [1]
C0339467
UMLS CUI [2]
C0259749
recurrent severe hypoglycemia as judged by the investigator
Beschreibung

severe hypoglycemia

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0020615
UMLS CUI [1,2]
C0205082
known or suspected allergy to trial product or related products
Beschreibung

allergy to trial product

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C3854006
use of any drug (except for ohas), which in the investigators opinion could interfere with the glucose level or body weight or any contraindication to metformin use or intolerance to metformin 1000 mg (prior to trial entry or during run-in period). stable doses, for 3 months or greater, of thyroid hormone replacement are allowed
Beschreibung

use of any drug contraindicated

Datentyp

boolean

Alias
UMLS CUI [1]
C3845816
known or suspected abuse of alcohol or narcotics
Beschreibung

abuse of alcohol or narcotics

Datentyp

boolean

Alias
UMLS CUI [1]
C0038586
current treatment with thiazolidinediones or chronic daily use of insulin (more than 7 days) within three months in the absence of intercurrent illness
Beschreibung

thiazolidinediones or chronic daily use of insulin

Datentyp

boolean

Alias
UMLS CUI [1]
C1257987
UMLS CUI [2]
C0021641
tsh (thyroid stimulating hormone) below 0.2 or above 15 u/ml
Beschreibung

thyroid stimulating hormone

Datentyp

boolean

Alias
UMLS CUI [1]
C0202230
type 1 or other specific causes of diabetes
Beschreibung

type 1 diabetes

Datentyp

boolean

Alias
UMLS CUI [1]
C0011854

Ähnliche Modelle

Eligibility Diabetes NCT01511198

  1. StudyEvent: Eligibility
    1. Eligibility Diabetes NCT01511198
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
type 2 diabetic
Item
type 2 diabetic
boolean
C0011860 (UMLS CUI [1])
oral hypoglycaemic agent
Item
treated with oha (oral hypoglycaemic agent monotherapy for at least 3 months. prior use of metformin is allowed
boolean
C0359086 (UMLS CUI [1])
BMI
Item
body mass index (bmi) between 27.0-42.0 kg/m^2 (inclusive)
boolean
C1305855 (UMLS CUI [1])
hba1c
Item
hba1c maximum 10% based on analysis from central laboratory
boolean
C0019018 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
cardiac problems
Item
cardiac problems
boolean
C0262402 (UMLS CUI [1])
untreated hypertension
Item
uncontrolled treated/untreated hypertension
boolean
C0020538 (UMLS CUI [1])
proliferative retinopathy or known autonomic neuropathy
Item
proliferative retinopathy or known autonomic neuropathy
boolean
C0339467 (UMLS CUI [1])
C0259749 (UMLS CUI [2])
severe hypoglycemia
Item
recurrent severe hypoglycemia as judged by the investigator
boolean
C0020615 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
allergy to trial product
Item
known or suspected allergy to trial product or related products
boolean
C0020517 (UMLS CUI [1,1])
C3854006 (UMLS CUI [1,2])
use of any drug contraindicated
Item
use of any drug (except for ohas), which in the investigators opinion could interfere with the glucose level or body weight or any contraindication to metformin use or intolerance to metformin 1000 mg (prior to trial entry or during run-in period). stable doses, for 3 months or greater, of thyroid hormone replacement are allowed
boolean
C3845816 (UMLS CUI [1])
abuse of alcohol or narcotics
Item
known or suspected abuse of alcohol or narcotics
boolean
C0038586 (UMLS CUI [1])
thiazolidinediones or chronic daily use of insulin
Item
current treatment with thiazolidinediones or chronic daily use of insulin (more than 7 days) within three months in the absence of intercurrent illness
boolean
C1257987 (UMLS CUI [1])
C0021641 (UMLS CUI [2])
thyroid stimulating hormone
Item
tsh (thyroid stimulating hormone) below 0.2 or above 15 u/ml
boolean
C0202230 (UMLS CUI [1])
type 1 diabetes
Item
type 1 or other specific causes of diabetes
boolean
C0011854 (UMLS CUI [1])

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video